MedTrace Logo

NMRC-M3V-Ad-PfCA Vaccine - Clinical Trial 1

NCT00392015 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 59

Last updated 2021-05-21

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine whether a new investigational malaria vaccine is safe, well tolerated and effective against experimental exposure to malaria when given to healthy people with no previous exposure to malaria. The vaccine consists of a modified form of a relatively common virus, adenovirus, that has been rendered incapable of replicating itself and modified to deliver the malaria gene of interest to the body's cells allowing the cell to manufacture the protein encoded by the gene and present it to the body's immune system in a more natural and presumably effective way.

Conditions

  • Plasmodium Falciparum

Interventions

BIOLOGICAL

NMRC-M3V-Ad-PfCA

Malaria Vaccine

BIOLOGICAL

NMRC-MV-Ad-PfC, NMRC-M3V-Ad-PfCA

Malaria Vaccines

Sponsors & Collaborators

  • United States Agency for International Development (USAID)

    collaborator FED

  • Congressionally Directed Medical Research Programs

    collaborator FED

  • Military Infectious Diseases Research Program (MIDRP)

    collaborator NETWORK

  • Naval Medical Research Center

    collaborator FED

  • U.S. Army Medical Research and Development Command

    lead FED

Principal Investigators

  • Cindy Tamminga, MD, MPH · Naval Medical Research Center

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
FACTORIAL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2006-10-12
Primary Completion
2016-06-02
Completion
2017-09-25

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00392015 on ClinicalTrials.gov